EN
X
NEWS
Here is the news of Plasmapp, which opens up the future with technology
News / Notice
[Exhibitions/Congress] Plasmapp is accelerating its expansion into the global market through MEDICA
Writer : plasmapp(business@plasmapp.com) Date : 2022-11-22 Hits : 47

Dental and orthopedic implant, as well as skin tissue surface treatment, new product launch expectations


Bio plasma deep tech company Plasmapp(CEO Youbong Lim) recently announced its participation in the 'Dusseldorf International Medical Equipment Exhibition (hereinafter MEDICA 2022)'. MEDICA 2022 is known as the world's largest medical device exhibition, with entry restrictions due to COVID-19 lifted, attracting more than 150 countries, 5,400 companies, and over 150,000 visitors.


 


In this exhibition, Plasmapp raised its ambition to expand its global market channels by showcasing the STERLINK sterilizer product (brand name STERLINK) certified by the US FDA and the medical implant surface treatment product (brand name ACTILINK) utilizing vacuum plasma technology for the first time in the world.


Based on this, Plasmapp is confident of achieving over 100% revenue growth for the third consecutive year until next year. In particular, there were reports of enthusiastic responses as they unveiled a new lineup of implant surface treatment products for the first time.


Plasmapp's surface treatment products successfully launched in the domestic dental market in the second half of 2021, and since obtaining US FDA certification from 2022, they have been rapidly expanding into regional markets such as the United States, Europe, and Japan, increasing the profitability of their business through market expansion.


Along with this, it is a strategy to achieve both revenue growth and business expansion by expanding the application areas from dental implants to orthopedic implants and skin tissue in the field.


CEO Youbong Lim said, "Recently, we have conducted large-scale supply contracts in the global medical device market, and with the launch of this new product, we are in discussions with global companies for new contracts." He added, "In the future, we will continue to invest in research and development to maintain a competitive edge in the global market with our innovative plasma technology."


Source: Medical Newspaper ( http://www.bosa.co.kr/ )

Prev. Plasmapp signs a supply contract worth 1.1 billion won with QMed of the U.S.
Next Plasmap, cumulative contract of KRW 330 billion through successive global supply contracts